

# Kent Academic Repository

## Full text document (pdf)

### Citation for published version

Parks, Jason C and McCallie, Blair R and Patton, Alyssa L and Al-Safi, Zain A and Polotsky, Alex J and Griffin, Darren K. and Schoolcraft, William B and Katz-Jaffe, Mandy G (2018) The impact of infertility diagnosis on embryo-endometrial dialogue. *Reproduction*, 155 (6). pp. 543-552. ISSN 1470-1626.

### DOI

<https://doi.org/10.1530/REP-17-0566>

### Link to record in KAR

<https://kar.kent.ac.uk/67206/>

### Document Version

Author's Accepted Manuscript

#### Copyright & reuse

Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions for further reuse of content should be sought from the publisher, author or other copyright holder.

#### Versions of research

The version in the Kent Academic Repository may differ from the final published version.

Users are advised to check <http://kar.kent.ac.uk> for the status of the paper. **Users should always cite the published version of record.**

#### Enquiries

For any further enquiries regarding the licence status of this document, please contact:

[researchsupport@kent.ac.uk](mailto:researchsupport@kent.ac.uk)

If you believe this document infringes copyright then please contact the KAR admin team with the take-down information provided at <http://kar.kent.ac.uk/contact.html>

# The impact of infertility diagnosis on embryo-endometrial dialogue

Jason C Parks<sup>1,2</sup>, Blair R McCallie<sup>1,2</sup>, Alyssa L Patton<sup>1</sup>, Zain A Al-Safi<sup>3</sup>, Alex J Polotsky<sup>3</sup>, Darren K Griffin<sup>2</sup>, William B Schoolcraft<sup>1</sup> and Mandy G Katz-Jaffe<sup>1</sup>

<sup>1</sup>Colorado Center for Reproductive Medicine, Lone Tree, Colorado, USA,

<sup>2</sup>University of Kent, Canterbury, UK and

<sup>3</sup>Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado, USA

## Abstract

Initial stages of implantation involve bi-directional molecular crosstalk between the blastocyst and endometrium. This study investigated an association between infertility etiologies, specifically advanced maternal age (AMA) and endometriosis, on the embryo-endometrial molecular dialogue prior to implantation. Co-culture experiments were performed with endometrial epithelial cells (EEC) and cryopreserved day 5 blastocysts ( $n = 41 \geq$  Grade 3BB) donated from patients presenting with AMA or endometriosis, compared to fertile donor oocyte controls. Extracellular vesicles isolated from co-culture supernatant were analyzed for miRNA expression and revealed significant alterations correlating to AMA or endometriosis. Specifically, AMA resulted in 16 miRNAs with increased expression ( $P \leq 0.05$ ) and strong evidence for negative regulation toward 206 target genes. *VEGFA*, a known activator of cell adhesion, displayed decreased expression ( $P \leq 0.05$ ), validating negative regulation by 4 of these increased miRNAs: miR-126; 150; 29a; 29b ( $P \leq 0.05$ ). In endometriosis patients, a total of 10 significantly altered miRNAs displayed increased expression compared to controls (miR-7b; 9; 24; 34b; 106a; 191; 200b; 200c; 342-3p; 484) ( $P \leq 0.05$ ), targeting 1014 strong evidence-based genes. Three target genes of miR-106a (*CDKN1A*, *E2F1* and *RUNX1*) were independently validated. Functional annotation analysis of miRNA-target genes revealed enriched pathways for both infertility etiologies, including disrupted cell cycle regulation and proliferation ( $P \leq 0.05$ ). These extracellular vesicle-bound secreted miRNAs are key transcriptional regulators in embryo-endometrial dialogue and may be prospective biomarkers of implantation success. One of the limitations of this study is that it was a stimulated, *in vitro* model and therefore may not accurately reflect the *in-vivo* environment.

## Introduction

The World Health Organization estimates that 10% of couples worldwide will struggle with infertility. Although a small number of these reproductive-age couples may succeed using conventional methods over many months and possibly years, most will require the use of assisted reproductive technologies (ARTs) and often *in vitro* fertilization (IVF) to establish a pregnancy (Thoma *et al.* 2013). Although considered relatively successful, 70% of IVF cycles will not result in a live birth (Weimar *et al.* 2013).

An intricate, bi-directional molecular dialogue between embryo and endometrium during the window of implantation, approximately 6–12 days post ovulation, is crucial for success (Wilcox *et al.* 1999). Without a precise interchange between the two, implantation will ultimately fail. Key genes involved with cell cycle regulation, as well as ion-binding and signal-transporting proteins, have been identified as contributors to the molecular dialogue between the embryo and a receptive endometrium by sampling the uterine microenvironment (Hannan *et al.* 2012, Ruiz-Alonso *et al.* 2012). MicroRNAs (miRNAs) also play an important role during the window of implantation and are expressed by both the implanting embryo and the receptive endometrium (Blakaj & Lin 2008, Laurent 2008). Altered expression of miRNAs (including miR-30b, miR-30d and miR-494) have been shown to regulate endometrial receptivity (Altmae *et al.* 2013).

An *in vitro* co-culture system can provide valuable insight into the initial bi-directional dialogue (Simon *et al.* 1998). *In vitro* studies utilizing an embryo/ endometrial co-culture system have observed key components of the molecular crosstalk between the embryo and endometrial epithelial cells (EEC). However, limited information regarding this interaction is known (Barmat *et al.* 1999, Simon *et al.* 1999, Rubio *et al.* 2000).

Our unique study utilized a human uterine luminal endometrial epithelial cell and human blastocyst co-culture system to investigate the molecular dialogue at the time of adhesion, in association with two major causes of female factor infertility (endometriosis and advanced maternal age). Advanced maternal age (AMA) is associated with a substantial linear decline in reproductive potential and is the major cause of female infertility (Rosenwaks *et al.* 1995). There are many factors contributing to the significant decrease in live births as women approach their 5th decade, including diminishing ovarian reserve (Zhang 2015), and the increase in oocyte chromosomal aneuploidy (Harton *et al.* 2013). Aneuploidy screening in IVF cycles has allowed for the transfer of euploid blastocysts, resulting in higher implantation rates, independent of maternal age (Schoolcraft *et al.* 2011). However, there are other variables beyond the oocyte/embryo chromosome constitution that impact the ability of a euploid blastocyst to successfully implant. Traditionally, AMA patients are shown to have a longer infertility duration and diminished ovarian reserve and require a higher dose of gonadotropins in controlled ovarian hyperstimulation, all resulting in poorer oocyte quality (Ocal *et al.* 2012).

Another pathological cause of infertility, widely diagnosed and treated within the field of reproductive medicine, is endometriosis. Endometriosis is a disease which causes tissue normally found within the uterus, to migrate and grow outside of it (Buck Louis *et al.* 2011). This debilitating disease is often painful, impacting a woman's quality of life, and greatly reduces the chances of conception. It is estimated that nearly half of all women with this diagnosis will have difficulty achieving a pregnancy (Practice Committee of the American Society for Reproductive Medicine 2006, Ozkan *et al.* 2008). The causes of endometriosis remain unclear; however a genetic predisposition is suspected as a common risk factor, including a family history of the condition (Wenzl *et al.* 2003). Several pathways have also been

identified within patients diagnosed with endometriosis which may contribute to the poor oocyte quality associated with the disease (Shebl *et al.* 2017). Within infertile populations, it is estimated that the prevalence of patients diagnosed with endometriosis is approximately 26.13% in women undergoing laparoscopy (Garcia- Velasco & Quea 2005, Rizk *et al.* 2015).

The aim of this study is to investigate these different primary infertility etiologies within a controlled co-culture system, to elucidate differences within the secretome. We found significant differences in the miRNA content within the extracellular vesicles of the supernatant, as well as differences in gene expression within the co-cultured endometrial cells and blastocysts which may impact endometrial function during the window of implantation.

## **Materials and methods**

### ***Embryos***

Surplus, cryopreserved, hatching, transfer-grade blastocysts as identified by the Gardner & Schoolcraft grading system (Gardner & Schoolcraft 1999) as  $\geq$ Grade 3BB on day 5 of embryonic development ( $n = 41$ ) were donated with patient consent and IRB approval. Blastocysts were derived from IVF cycles: young fertile oocyte donor controls (fertile control group) with no history of female or male factor infertility, based on WHO guidelines (maternal age  $\leq 32$  years old, BMI  $< 29$ , non-smoker, non-drug user, with normal ovarian reserve and regular menstrual cycles,  $n = 15$ ), infertile women of AMA group without pre-implantation genetic diagnosis ( $\geq 39$  years or older, with no other infertility diagnosis,  $n = 14$ ), and younger female patients diagnosed with endometriosis as the only cause of infertility (mean maternal age of 34.3, with 11 of the 12 patients  $\leq 33$  years old,  $n = 12$ ). Subjects underwent an ovarian stimulation protocol based on clinical discretion which included gonadotropin-releasing hormone (GnRH) agonist down-regulation, microdose GnRH agonist flare or GnRH antagonist with Menopur (Ferring Pharmaceuticals, Saint-Prex, Switzerland) or Bravelle (Ferring Pharmaceuticals) with or without clomiphene citrate. Final oocyte maturation trigger was induced when the lead follicle reached 20 mm mean diameter using an intramuscular injection of hCG, a subcutaneous injection of leuprolide acetate, or a combination of both, based on clinical judgment. Routine oocyte retrieval was performed transvaginally under ultrasound guidance 35 h post trigger. Patients within the endometriosis group were asymptomatic at the time of their oocyte retrieval and biopsy. Patients were excluded from the study if they had any other infertility comorbidities including polycystic ovary syndrome and depleted ovarian reserve. Embryos were vitrified and warmed according to routine laboratory procedures described previously (Kuwayama *et al.* 2005). Total time spent frozen varied, with an average time of approximately 4 years.


### ***Endometrial biopsies***

Endometrial biopsies were collected from either young, fertile oocyte donors (fertile control group,  $n = 7$ ) or from patients diagnosed with endometriosis who were currently asymptomatic at the time of their oocyte retrieval ( $n = 2$ ). Subjects were stimulated as described earlier. Endometrial biopsies measured 1.5–3.0 cm in length and approximately 0.5 cm in diameter. For every endometrial biopsy collected, tissue was minced into  $< 1$  mm sections

and incubated at 4°C overnight in a 0.1% collagenase solution (Sigma-Aldrich). The primary epithelial endometrial cells (EEC) were isolated by vigorously vortexing and rinsing the cell milieu in 10 mL of room temperature DMEM (Sigma-Aldrich), prior to resting the cells for 5–10 min as they settled into distinct layers of EEC and stromal cells. The supernatant containing stromal cells was then removed and the process was repeated three times until no further stromal cells remained. 500 µL of the EEC/DMEM was then added to 6 wells of a Falcon Multiwell 24-well Tissue Culture Plate (Corning Incorporated) (Mercader *et al.* 2003). Cells were cultured in a media composed of 75% Dulbecco Modified Eagle Medium (Sigma) and 25% MCDB- 105 (Sigma) containing antibiotics, 5 µg/mL insulin (Sigma) and supplemented with 10% exosome-depleted fetal bovine serum (System Biosciences, Palo Alto, CA, USA) and observed daily to monitor the development of an EEC monolayer. The monolayer reached acceptable levels of well coverage at >65% after 4–6 days. The growth medium was then replaced with a serum-free medium for embryo development and supplemented with 4% recombinant human serum albumin (Vitrolife, Englewood, CO, USA). For each endometrial biopsy processed, 4–6 wells received an individual thawed blastocyst which was co-cultured for 48 h at 5% O<sub>2</sub> and 6% CO<sub>2</sub> at 37°C based on current laboratory practices for human blastocyst culture (Kovacic 2012).

### ***Co-culture collection***

Blastocysts were co-cultured together for 48 h prior to collection. AMA or fertile control donor blastocysts were co-cultured with fertile control donor endometrial tissue. Additionally, the endometriosis subjects were divided into three groups: fertile control donor blastocysts co-cultured with fertile control donor endometrium (CD), fertile control donor blastocysts co-cultured with endometrial cells from patients diagnosed with endometriosis (ED) and blastocysts and endometrial cells that were both obtained from patients diagnosed with endometriosis (EE). Adhesion by the blastocyst to the endometrial monolayer was observed twice in the AMA group, twice in the fertile control group and once in both of the endometriosis groups. Adhered blastocysts were gently scraped off the monolayer prior to collection. Following co-culture, blastocysts were graded and rinsed in 10% phosphate buffered saline-bovine serum albumin (PBS-BSA) before lysis in 10 µL of extraction buffer (PicoPureRNA Isolation Kit, Thermo Fisher Scientific). Co-culture supernatant was collected (500 µL) and snap-frozen in liquid nitrogen. The monolayer was visually measured for 100% confluence, then rinsed with DPBS (Thermo Fisher) and incubated at 37°C with 1× diluted TrypLESelect (10×) (Thermo Fisher) until cells lifted from the bottom of the plate (5–15 min). Each well of EEC were collected individually. The pelleted EEC were lysed with 50 µL Extraction Buffer (PicoPureRNA Isolation Kit, Thermo Fisher) and snap-frozen with liquid nitrogen. All samples were stored at –80°C until further analysis (Fig. 1 ).



**Figure 1** Experimental design for embryo co-culture with cultured endometrial cells.

### ***Supernatant extracellular vesicle miRNA analysis***

Extracellular vesicles were isolated using Total Exosome Isolation Reagent (from cell culture media) (Thermo Fisher). 350  $\mu$ L of supernatant was combined with 175  $\mu$ L of reagent and vortex-mixed prior to an overnight incubation at 4°C. Samples were centrifuged under refrigerated conditions for 1 h, then the supernatant was aspirated and discarded. The resulting pellet was lysed in 10  $\mu$ L of lysis solution containing DNase (Taqman MicroRNA Cells-to-CT Kit, Thermo Fisher) and incubated at room temperature for 8 min. Lysed miRNA was reverse-transcribed using the Taqman MicroRNA Reverse Transcription Kit with MegaPlex RT Human Primer Pool A (Thermo Fisher) in a final volume of 7.5  $\mu$ L under the following thermal cycling conditions: 40 cycles at 16°C for 2 min, 42°C for 1 min and 50°C for 1 s followed by a hold for 5 min at 85°C. cDNA was pre-amplified using the Taqman PreAmp Mastermix with MegaPlex PreAmp Human Primer Pool A (Thermo Fisher). 100  $\mu$ L of the diluted pre-amplified product was added to each well of the Taqman Human MicroRNA Array Card A and was then run on the 7900HT Fast Real-Time PCR System (Thermo Fisher) under the following thermal cycling conditions: 50°C for 2 min, 94.5°C for 10 min and 40 cycles at 97°C for 30 s and 59.7°C for 1 min. Data were analyzed using the RQ Manager 1.2.1 (Thermo Fisher), and statistical analysis was performed using REST 2009 software (Qiagen). miRNAs that displayed significantly altered expression profiles were further investigated for target gene analysis using miRTarBase (<http://mirtarbase.mbc.nctu.edu.tw/index.php>), a database of experimentally validated miRNA-target interactions that are classified as strong evidence based if there is sufficient published empirical evidence.

### ***Blastocyst gene expression***

Individual blastocysts stored in 10  $\mu$ L of extraction buffer (PicoPure RNA Isolation Kit, Thermo Fisher) were incubated at 42°C for 30 min prior to isolating RNA. This procedure entailed adding 1 volume of 70% EtOH to each sample before transferring to a pre-conditioned purification column. Samples were then DNase-treated using the RNase-Free DNase Set (Qiagen) and eluted in 20  $\mu$ L following several washes. All 20  $\mu$ L of purified total RNA was reverse-transcribed using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher) in a final volume of 40  $\mu$ L. The reaction occurred in a thermal cycler at 25°C for 10 min followed by 37°C for 2 h. cDNA samples were diluted 1:5 with nuclease-free water and a 5  $\mu$ L template was used for real-time PCR using the Power SYBR Green PCR Master Mix (Thermo Fisher) and a 5  $\mu$ M primer mix (forward + reverse) in a 25  $\mu$ L final volume. Duplicates of each sample were performed on the ABI 7300 Real-Time PCR System under the following thermal cycling conditions: 95°C for 10 min, 40 cycles at 95°C for 15 s and 60°C for 1 min, followed by a dissociation stage to determine melt temperatures. Standard curves were also employed for each gene using Universal Human Reference RNA (Agilent) in 10-fold serial dilutions and an internal housekeeping gene (*PPIA*) was used to normalize each sample.

### ***Endometrial cell molecular analysis***

EEC samples were lysed in 75  $\mu$ L of lysis solution and miRNAs were isolated using the RNeasy-Micro Kit (Thermo Fisher) which required the addition of 1.25 volumes of 100% EtOH prior to loading onto a micro filter cartridge assembly. Samples were DNase-treated in the same manner as the blastocyst samples, and washed several times before eluting in 10  $\mu$ L of elution solution previously heated to 75°C (performed twice for maximum recovery, 20  $\mu$ L final volume). miRNA samples were then concentrated down to a 10  $\mu$ L volume using a vacuum concentrator (Vacufuge Plus, Eppendorf).

miRNA samples were pre-amplified, diluted and evaluated using the Taqman Human MicroRNA Array Card A (Thermo Fisher) as described in the earlier supernatant exosome miRNA analysis section. Data were analyzed using the RQ Manager 1.2.1 (Thermo Fisher) and statistical analysis was performed as described in the following.


### ***Statistical analysis***

A Mann–Whitney *U* test was used to compare differences in the age of the donor women (fertile control, AMA and endometriosis blastocysts), with significance at  $P \leq 0.05$ . The PCR reaction efficiencies recorded  $R^2$  values  $\geq 0.9$  and correlation coefficients were calculated to be  $>0.99$ . Statistical analysis was performed with REST-2009 software (Qiagen) which uses bootstrap randomization techniques to correct for exact PCR efficiencies with mean crossing point deviations between sample and control groups to determine an expression ratio that is tested for significance by a pair wise fixed reallocation randomization test. The standard error and the 95% confidence interval (CI) given by REST-2009 software are not derived from Ct values. They are the standard error and the CI for the 50,000 iterations the program runs to calculate the *P* value; thus, no error bars are generated for graphical presentation. Gene expression fold differences with  $P \leq 0.05$  were considered statistically significant.


## **Results**

### Co-culture of AMA blastocysts and fertile control blastocysts

The age of the donors in the fertile control blastocyst group were significantly different than those in the AMA blastocyst group ( $P \leq 0.05$ ). Isolated cargo of extracellular vesicles from supernatant collected after co-culture of fertile endometrial epithelial cells with blastocysts from infertile AMA patients revealed altered miRNA expression profiles compared to fertile control blastocysts. A total of 16 miRNAs showed increased expression and 2 exhibited reduced expression in association with the maternal age of the blastocyst relative to the internal housekeeping gene *RNU48* ( $P \leq 0.05$ , Fig. 2). Target gene investigation of these 18 altered miRNAs using miRTarBase (<http://mirtarbase.mbc.nctu.edu.tw/index.php>) revealed 576 genes, 206 of which displayed strong evidence as defined by Western blot, qPCR or reporter assay as described previously. Of these strong evidence-based genes, *VEGFA* was identified as a target gene, specifically regulated by four of the altered miRNAs: miR-126, 150, 29a and 29b. Examination of *VEGFA* transcription by qPCR observed decreased expression in both the corresponding endometrial epithelial cells and blastocysts from infertile AMA patients following co-culture, specifically a 50% fold change reduction compared to fertile controls ( $P \leq 0.05$ ; Fig. 3).



**Figure 2** Differential expression of extracellular vesicle-bound miRNAs in co-culture supernatant in association with maternal age ( $*P \leq 0.05$ ).



**Figure 3** Target gene *VEGFA* expression in endometrial cells (A) and AMA blastocysts (B) compared to young fertile controls ( $*P \leq 0.05$ ).



### ***Co-culture of endometriosis blastocysts or fertile control blastocysts on donor endometrium or endometriosis endometrium***


The ages of the donors in the fertile control blastocyst group were not significantly different from those in the endometriosis blastocyst group ( $P \geq 0.05$ ; ns). Isolated extracellular vesicles from supernatant collected after co-culture of endometriosis EEC with blastocysts from endometriosis patients revealed an altered miRNAome compared to fertile controls. Specifically, 10 miRNAs showed significant decreased expression including miR-7b, miR-24, miR-34b, miR-200c, miR-342-3p, miR-9, miR-484, miR-200b, miR-106a and miR-191 ( $P \leq 0.05$ ; Figs 4 and 5) compared to fertile control endometrium co-cultured with fertile control blastocysts. Using mirTarBase, strong evidence-based target genes were revealed, including, among others, 27 target genes for miR-106a. Of these 27 target genes *CDKN1A*, *E2F1* and *RUNX1* were chosen for further investigation because of their known roles in association with implantation in murine (*Cdkn1a*) (Das 2009) and human models (*E2F1* and *RUNX1*) (Tapia *et al.* 2011, Tapia-Pizarro *et al.* 2014). qPCR analysis observed increased expression of *CDKN1A* in endometriosis blastocysts compared to fertile controls when co-cultured with fertile control derived EEC ( $P \leq 0.05$ ). This expression was further increased when endometriosis derived blastocysts were co-cultured with endometriosis derived EEC ( $P \leq 0.05$ ; Fig. 6A). Endometriosis EEC co-cultured with fertile control blastocysts displayed increased expression of *E2F1* and *RUNX1* ( $P \leq 0.05$ ). This significant difference in expression was further increased when endometriosis derived blastocysts were co-cultured using endometriosis derived EEC ( $P \leq 0.05$ ; Fig. 6B).

### ***Gene ontology and pathway analysis***


DAVID Bioinformatics Resources 6.8 (<https://david.ncifcrf.gov/>) was utilized for functional annotation clustering analyses of differentially expressed miRNAs to explore the GO biological processes and pathways, common to both infertility etiologies, and included cellular development, proliferation and cell cycle regulation.

The enriched pathways and processes that were identified as being specific to only the AMA etiology included PI3K-Akt and vascular endothelial growth factor (VEGF) signaling, as well as biological processes involving cellular development and migration, adhesion and cell cycle regulation ( $P \leq 0.05$ ; Supplementary Table 1, see section on supplementary data given at the end of this article).


For the endometriosis etiology group, enriched biological processes and pathways crucial for development and implantation were revealed within functional annotation clusters of the 1014 strong evidence-based target genes, including positive regulation of cell proliferation, G1/S transition of mitotic cell cycle and the p53 signaling pathway and angiogenesis ( $P \leq 0.05$ ). Additionally, cell cycle regulation and arrest, positive regulation of cell proliferation, negative regulation of apoptotic processes and negative regulation of G1/S transition of mitotic cell cycles were also identified (Supplementary Table 2).



**Figure 4** Experimental groups (CD = fertile control endometrium/fertile control blastocyst; ED = endometriosis endometrium/fertile control blastocyst; EE = endometriosis endometrium/endometriosis blastocyst) and the affected miRNAs for embryos and endometrial cells derived from patients diagnosed with endometriosis compared with fertile control.



**Figure 5** Extracellular vesicle-bound microRNA expression of co-culture supernatant. Endometriosis derived blastocysts cultured on a monolayer of endometriosis derived endometrial tissue and fertile control derived endometrial tissue, fertile control oocyte derived blastocysts ( $*P \leq 0.05$ ).



**Figure 6** (A) miR-106a target gene validation of endometriosis derived blastocysts revealed significantly increased expression of *CDKN1A* when co-cultured with endometriosis derived endometrial cells compared to fertile control (CD = fertile control endometrium/ fertile control blastocyst; ED = endometriosis endometrium/fertile control blastocyst; EE = endometriosis endometrium/endometriosis blastocyst) ( $*P \leq 0.05$ ). (B) miR-106a target gene validation of endometriosis derived endometrial cells co-cultured with endometriosis derived blastocysts revealed significantly increased expression of *E2F1* and *RUNX1* compared to fertile control derived controls (CD = fertile control endometrium/fertile control blastocyst; ED = endometriosis endometrium/fertile control blastocyst; EE = endometriosis endometrium/endometriosis blastocyst) ( $*P \leq 0.05$ ).

## Discussion

This is a novel study investigating the bi-directional molecular communication at the time of implantation in association with infertility etiologies. Blastocysts from patients presenting with AMA or endometriosis were co-cultured on a monolayer of endometrial cells to capture the molecular dialogue between a blastocyst and the endometrium during the initial stages of implantation. Specific extracellular vesicle-bound miRNAs derived from co-culture supernatant were identified to have significantly altered expression in association with AMA or endometriosis, highlighted by the differences within embryo-endometrial communication depending on the source of the embryo or endometrium. This impacted downstream target gene expression in either blastocysts or endometrial cells during the window of implantation.

### **Advanced maternal age**

It is well documented that infertile women presenting with advanced maternal age have some of the poorest prognoses with regard to oocyte and blastocyst quality. Additionally, there is some evidence that the endometrium is also affected by advanced age, resulting in embryo-endometrial asynchrony (Shapiro *et al.* 2016). The molecular dialogue between the embryo and endometrium is crucial for successful implantation, and it is believed that miRNA-bound extracellular vesicles are involved in this bi-directional molecular communication.

A total of 18 extracellular vesicle-bound miRNAs displayed altered expression with the presence of AMA blastocysts. One example was miR-150, a critically important miRNA for lineage cell differentiation, which also plays a role in mediating an appropriate inflammatory response within the endometrial environment. This response includes not only the endometrial epithelial cells and stromal cells, but also the immune-related cells and vasculature (Pan & Chegini 2008, Elton *et al.* 2013, Goossens *et al.* 2013). Pregnancy is a pro-inflammatory state and molecular miscommunication may result in an improperly coordinated auto-immune response, leading to inflammation at the implantation site, causing implantation failure and embryonic death. This is a delicate balance, and if the immune response is too great or insufficient, implantation potential may be impacted (Clark 2008). miR-150 is also a regulatory miRNA for the platelet-derived growth factor/VEGF family of genes, responsible for both angiogenesis and vasculogenesis, and is vital for successful embryo implantation. It has also been shown that supplementing embryo culture media with VEGF had beneficial effects with regard to post-compaction mouse embryo development, outgrowth, implantation and fetal development (Binder *et al.* 2014, 2016).

*VEGFA* is a glycosylated mitogen that specifically acts on endothelial cells with various effects, including mediating vascular permeability, angiogenesis, cell growth and cell migration and inhibiting apoptosis. Treatment of human endometrial cells with recombinant human VEGFA protein has been found to significantly increase endometrial cell adhesion (Hannan *et al.* 2011). In this study, *VEGFA* displayed a significantly lower expression in AMA samples ( $P \leq 0.05$ ), which may lead to dysregulated cellular function and increased apoptosis. This decrease in *VEGFA* expression may be indicative of the compromised communication between the AMA blastocyst and fertile control endometrium.

An additional altered miRNA observed in extracellular vesicles following co-culture was miR-135a with an 8-fold decrease in expression in AMA blastocysts ( $P \leq 0.05$ ). A previous study observed that increased expression of miR-135a during pre-implantation embryo development led to the down-regulation of E3 ubiquitin ligase seven in absentia homologue 1A (*SIAH1A*) expression (Pang *et al.* 2011). The *SIAH1A* protein is involved in many cellular processes including apoptosis, TNF-alpha signaling and cell cycle regulation (Relaix *et al.* 2000). Nearly a third of the zygotes injected with miR-135a inhibitor were observed to arrest in development. The mechanism for this disruption is believed to be due to dysregulated proteosomal degradation, possibly controlling the expression of chemokines in DNA-binding protein (Pang *et al.* 2011). miR-135a has also been correlated to increased apoptosis resistance in cancer cells by *BCL2* regulation, a protein which determines cell survival and death through the mitochondrial apoptotic signaling pathway. Dysregulation of *BCL2* and disruption of the apoptotic pathway resulted in interference of not only the establishment of pregnancy, but also pregnancy

maintenance if successful implantation was able to occur at all (Mathew *et al.* 2009, Pan *et al.* 2014). The dysregulation of miR-135a observed in our samples suggests a decline in the cellular regulation of blastocysts derived from AMA patients, thus decreasing their viability and implantation potential.

Another miRNA found in the extracellular vesicles of the supernatant that displayed significantly disrupted differential expression was miR-449b. One strong, evidence-based target gene for miR-449b is *NOTCH1* which has demonstrated its ability to act as a promoter of centriole multiplication multiciliogenesis by repressing the Delta/Notch pathway in *Xenopus laevis* embryonic dermis (Marcet *et al.* 2011). It is currently unknown precisely how mammalian cells are affected by this pathway; however it is hypothesized that, rather than the cilia found in *Xenopus* cells, it is the formation of the pseudopodia within the blastocyst trophoctoderm that is being directly regulated (Goossens *et al.* 2013). miR-449b showed significantly increased expression in the co-culture supernatant of AMA blastocysts, which may indicate compromised trophoctoderm formation, leading to an increase in failed implantation as observed clinically in this patient population.

### **Endometriosis**

Endometriosis is a disease characterized by an abnormal, and in many cases, compromised endometrium. The impact this diagnosis bears on the bi-directional embryo-endometrial dialogue at the time of implantation is largely unexplored. In our study, co-culture of endometriosis endometrium with blastocysts derived from patients diagnosed with endometriosis displayed significantly decreased extracellular miRNA, from within the isolated extracellular vesicles, when compared to fertile control endometrium with fertile control derived blastocysts for 10 key miRNAs ( $P \leq 0.05$ ). Of particular interest was miR-106a, commonly associated with adherens junctions, receptor interactions, metabolic pathways and VEGF signaling. In one study utilizing a uterine cavity lavage, miR-106a was identified in the exosomes found within the mucus near the time implantation may occur. It is suspected that as the blastocyst transitions toward the implantation site and begins to adhere, exosomes trapped within the mucus on the luminal surface of the endometrium release miRNAs which contribute to endometrial-embryo crosstalk by binding to the trophoctoderm cells themselves (Ng *et al.* 2013). miR-106a has also revealed itself to be a strong identifying biomarker for various types of cancer where it is often down-regulated (Wang 2016). MiRTarBase target gene analysis of miR-106a identified 29 strong evidence-based target genes, including *CDKN1A*, *E2F1* and *RUNX1*.

*CDKN1A* works in conjunction with *TP53* and is linked to stress response in the G1 phase. If this stress response continues to cascade, it causes arrested cell cycle, potentially compromising the viability of embryos, and also contributing to possible de-regulation of the endometrium itself (Sharma *et al.* 2016). *CDKN1A* expression has been shown to induce cellular growth, arrest, terminal differentiation or apoptosis (Ying *et al.* 2011). Altered aberrant *CDKN1A* expression is also believed to play a vital role in the pathogenesis of specific cancer types, including ovarian and uterine carcinomas (Elbendary *et al.* 1996). Our results demonstrate altered *CDKN1A* gene expression in blastocysts derived from patients diagnosed

with endometriosis, which may negatively impact their viability, and also contribute to the reduced implantation potential of embryos derived from this patient population.

*E2F1* is a transcription factor that plays a crucial role in the control of the cell cycle and can mediate apoptosis. Over-expression of *E2F1* in myoblasts has demonstrated proliferation stimulation while also inhibiting differentiation (Luo *et al.* 2016). *E2F1* induces the transcription of several genes involved in cell cycle entry, resulting in either the induction or inhibition of apoptosis. This influence leads to both negative and positive feedback loops, having a critical impact on the outcome of the cell's fate. The *E2F1* protein has also shown increased expression in patients diagnosed with endometrial cancer, where the cell cycle becomes accelerated and irregular (Mints *et al.* 2016). Decreased expression of miR-106a can increase p53 expression in human glioma cells by inhibiting *E2F1*, negatively effecting cell proliferation and inducing apoptosis (Yang *et al.* 2011, Feng *et al.* 2013). Within the endometrium derived from patients diagnosed with endometriosis, irregular feedback loops may lead to inhibited differentiation, compromising the viability of the implantation site.

*RUNX1* is also a transcription factor that, when over expressed, increases apoptosis. In a mouse embryo knockout study, embryos with homozygous mutations on *Runx1* terminated after 12.5 days of development, and suffered from a lack of fetal liver hematopoiesis as well as hemorrhaging of the central nervous system (Okuda *et al.* 1996, Wang *et al.* 1996). Similar to *E2F1*, over-expression of the *RUNX1* protein has been linked to various forms of cancer, including endometrial and endometrioid carcinomas (Planaguma *et al.* 2004, Abal *et al.* 2006). In mice, *Runx1* also plays an important role in regulating the gene expression of *Ada* in trophoblast cell lineage which is critical for embryo development (Schaubach *et al.* 2006). In our study, endometriosis derived endometrium showed increased expression of *RUNX1* that may lead to decreased implantation potential by compromising hematopoiesis and influencing the gene expression of placental *ADA*.

DAVID functional annotation bioinformatics microarray analysis revealed further dysfunction within the expression of miRNAs for both infertility etiologies, in relation to GO biological processes and pathways. When comparing the three different design groups, we found that miR-24, 34b and 484 were not commonly expressed between the groups of ED vs CD and EE vs CD, highlighting a subset of developmental pathways that were affected by the presence of endometrial cells from patients diagnosed with endometriosis (Supplementary Table 3). Interestingly, there were also no significant differences in miRNA expression between the groups of EE and ED ( $P > 0.05$ ), which may signify that the endometriosis EEC are contributing the majority of the extracellular vesicles to the supernatant and may impact the developmental potential of the implanting blastocyst. One commonality between the endometriosis and AMA groups was the focus on cell cycle regulation. This may be indicative of compromised dialogue within the extracellular matrix. As the window of implantation approaches, specific auto-induction loops must occur to mediate the critical crosstalk between a competent blastocyst and the uterine epithelium at the implantation site (Hamatani *et al.* 2004). If these critical processes and pathways are disrupted, the resulting cell cycle dysregulation may contribute to a harsh environment, unsuitable for implantation and further development necessary for a viable pregnancy by preventing firm adhesion between the blastocyst and the uterine epithelium (Wang *et al.* 2008).

A few limitations of this study include the source of the endometrial biopsy. These biopsies were taken at the time of oocyte retrieval from women undergoing controlled ovarian stimulation. It has been shown that this leads to estrogen-dependent changes in the protein profiles of the endometrial compartments which may affect endometrial receptivity (Ullah *et al.* 2017). Furthermore, due to the scarcity of research materials, these protein profile alterations were unable to be validated further by ELISA analysis.

In conclusion, our study displayed a theme of compromised cellular communication in blastocysts and endometrium derived from patients diagnosed with AMA or endometriosis. These alterations may account for the lower implantation potential and clinical outcomes observed for these infertile patient populations. Any compromise in the delicate embryo-endometrial molecular dialogue, either autocrine or paracrine, may impact transcription levels of key miRNAs and their target signaling molecules, resulting in significantly lower potential for reproductive success. Further investigation of the bi-directional molecular dialogue may help elucidate important implantation biomarkers during this critical time point, and advance our understanding of reproductive success.

### **Supplementary data**

This is linked to the online version of the paper at <https://doi.org/10.1530/REP-17-0566>.

### **Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

### **Funding**

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

### **Acknowledgements**

The authors would like to acknowledge the physicians, embryologists and surgical staff at the Colorado Center for Reproductive Medicine for their assistance with subject recruitment and sample collection. The authors would also like to thank Professor Carlos Simón and Fundación IVI for sharing their co-culture experimental protocols.

### **References**

- Abal M, Planaguma J, Gil-Moreno A, Monge M, Gonzalez M, Baro T, Garcia A, Castellvi J, Ramon YCS, Xercavins J et al.** 2006 Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors. *Histology and Histopathology* **21** 197–204. (<https://doi.org/10.14670/HH-21.197>)
- Altmae S, Martinez-Conejero JA, Esteban FJ, Ruiz-Alonso M, Stavreus-Evers A, Horcajadas JA & Salumets A** 2013 MicroRNAs miR-30b, miR-30d, and miR-494 regulate human endometrial receptivity. *Reproductive Sciences* **20** 308–317. (<https://doi.org/10.1177/1933719112453507>)

- Barmat LI, Liu HC, Spandorfer SD, Kowalik A, Mele C, Xu K, Veeck L, Damarzio M & Rosenwaks Z** 1999 Autologous endometrial co-culture in patients with repeated failures of implantation after in vitro fertilization-embryo transfer. *Journal of Assisted Reproduction and Genetics* **16** 121–127. (<https://doi.org/10.1023/A:1022575630105>)
- Binder NK, Evans J, Gardner DK, Salamonsen LA & Hannan NJ** 2014 Endometrial signals improve embryo outcome: functional role of vascular endothelial growth factor isoforms on embryo development and implantation in mice. *Human Reproduction* **29** 2278–2286. (<https://doi.org/10.1093/humrep/deu211>)
- Binder NK, Evans J, Salamonsen LA, Gardner DK, Kaitu'u-Lino TJ & Hannan NJ** 2016 Placental growth factor is secreted by the human endometrium and has potential important functions during embryo development and implantation. *PLoS ONE* **11** e0163096. (<https://doi.org/10.1371/journal.pone.0163096>)
- Blakaj A & Lin H** 2008 Piecing together the mosaic of early mammalian development through microRNAs. *Journal of Biological Chemistry* **283** 9505–9508. (<https://doi.org/10.1074/jbc.R800002200>)
- Buck Louis GM, Hediger ML, Peterson CM, Croughan M, Sundaram R, Stanford J, Chen Z, Fujimoto VY, Varner MW, Trumble A et al.** 2011 Incidence of endometriosis by study population and diagnostic method: the ENDO study. *Fertility and Sterility* **96** 360–365. (<https://doi.org/10.1016/j.fertnstert.2011.05.087>)
- Clark DA** 2008 Immunological factors in pregnancy wastage: fact or fiction. *American Journal of Reproductive Immunology* **59** 277–300. (<https://doi.org/10.1111/j.1600-0897.2008.00580.x>)
- Das SK** 2009 Cell cycle regulatory control for uterine stromal cell decidualization in implantation. *Reproduction* **137** 889–899. (<https://doi.org/10.1530/REP-08-0539>)
- Elbendary AA, Cirisano FD, Evans AC Jr, Davis PL, Iglehart JD, Marks JR & Berchuck A** 1996 Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. *Clinical Cancer Research* **2** 1571–1575.
- Elton TS, Selemon H, Elton SM & Parinandi NL** 2013 Regulation of the MIR155 host gene in physiological and pathological processes. *Gene* **532** 1–12. (<https://doi.org/10.1016/j.gene.2012.12.009>)
- Feng S, Cao Z & Wang X** 2013 Role of aryl hydrocarbon receptor in cancer. *Biochimica et Biophysica Acta* **1836** 197–210. (<https://doi.org/10.1016/j.bbcan.2013.05.001>)
- Garcia-Velasco JA & Quea G** 2005 Medical treatment of endometriosis. *Minerva Ginecologica* **57** 249–255.
- Gardner DK & Schoolcraft WB** 1999. In vitro culture of human blastocysts. In *Towards Reproductive Certainty: Fertility and Genetics Beyond.*, pp 378–388. Carnforth: Parthenon Press
- Goossens K, Mestdagh P, Lefever S, Van Poucke M, Van Zeveren A, Van Soom A, Vandesompele J & Peelman L** 2013 Regulatory microRNA network identification in bovine blastocyst development. *Stem Cells and Development* **22** 1907–1920. (<https://doi.org/10.1089/scd.2012.0708>)
- Hamatani T, Daikoku T, Wang H, Matsumoto H, Carter MG, Ko MS & Dey SK** 2004 Global gene expression analysis identifies molecular pathways distinguishing blastocyst dormancy and activation. *PNAS* **101** 10326–10331. (<https://doi.org/10.1073/pnas.0402597101>)



- Hannan NJ, Paiva P, Meehan KL, Rombauts LJ, Gardner DK & Salamonsen LA** 2011 Analysis of fertility-related soluble mediators in human uterine fluid identifies VEGF as a key regulator of embryo implantation. *Endocrinology* **152** 4948–4956. (<https://doi.org/10.1210/en.2011-1248>)
- Hannan NJ, Nie G, Rainzcuk A, Rombauts LJ & Salamonsen LA** 2012 Uterine lavage or aspirate: which view of the intrauterine environment? *Reproductive Sciences* **19** 1125–1132. (<https://doi.org/10.1177/1933719112443879>)
- Harton GL, Munne S, Surrey M, Grifo J, Kaplan B, McCulloh DH, Griffin DK, Wells D & PGD Practitioners Group** 2013 Diminished effect of maternal age on implantation after preimplantation genetic diagnosis with array comparative genomic hybridization. *Fertility and Sterility* **100** 1695–1703. (<https://doi.org/10.1016/j.fertnstert.2013.07.2002>)
- Kovacic B** 2012 Culture systems: low-oxygen culture. *Methods in Molecular Biology* **912** 249–272.
- Kuwayama M, Vajta G, Kato O & Leibo SP** 2005 Highly efficient vitrification method for cryopreservation of human oocytes. *Reproductive BioMedicine Online* **11** 300–308. ([https://doi.org/10.1016/S1472-6483\(10\)60837-1](https://doi.org/10.1016/S1472-6483(10)60837-1))
- Laurent LC** 2008 MicroRNAs in embryonic stem cells and early embryonic development. *Journal of Cellular and Molecular Medicine* **12** 2181–2188. (<https://doi.org/10.1111/j.1582-4934.2008.00513.x>)
- Luo W, Li G, Yi Z, Nie Q & Zhang X** 2016 E2F1-miR-20a-5p/20b-5p auto-regulatory feedback loop involved in myoblast proliferation and differentiation. *Scientific Reports* **6** 27904. (<https://doi.org/10.1038/srep27904>)
- Marcet B, Chevalier B, Luxardi G, Coraux C, Zaragosi LE, Cibois M, Robbe- Sermesant K, Jolly T, Cardinaud B, Moreilhon C et al.** 2011 Control of vertebrate multiciliogenesis by miR-449 through direct repression of the Delta/Notch pathway. *Nature Cell Biology* **13** 693–699. (<https://doi.org/10.1038/ncb2241>)
- Mathew SJ, Haubert D, Kronke M & Leptin M** 2009 Looking beyond death: a morphogenetic role for the TNF signalling pathway. *Journal of Cell Science* **122** 1939–1946. (<https://doi.org/10.1242/jcs.044487>)
- Mercader A, Garcia-Velasco JA, Escudero E, Remohi J, Pellicer A & Simon C** 2003 Clinical experience and perinatal outcome of blastocyst transfer after coculture of human embryos with human endometrial epithelial cells: a 5-year follow-up study. *Fertility and Sterility* **80** 1162–1168. ([https://doi.org/10.1016/S0015-0282\(03\)01178-6](https://doi.org/10.1016/S0015-0282(03)01178-6))
- Mints M, Mushtaq M, Iurchenko N, Kovalevska L, Stip MC, Budnikova D, Andersson S, Polischuk L, Buchynska L & Kashuba E** 2016 Mitochondrial ribosomal protein S18-2 is highly expressed in endometrial cancers along with free E2F1. *Oncotarget* **7** 22150–22158. (<https://doi.org/10.18632/oncotarget.7905>)
- Ng YH, Rome S, Jalabert A, Forterre A, Singh H, Hincks CL & Salamonsen LA** 2013 Endometrial exosomes/microvesicles in the uterine microenvironment: a new paradigm for embryo-endometrial cross talk at implantation. *PLoS ONE* **8** e58502. (<https://doi.org/10.1371/journal.pone.0058502>)
- Ocal P, Cift T, Bulut B, Balcan E, Cepni I, Aydogan B & Irez T** 2012 Recurrent implantation failure is more frequently seen in female patients with poor prognosis. *International Journal of Fertility and Sterility* **6** 71–78.

- Okuda T, van Deursen J, Hiebert SW, Grosveld G & Downing JR** 1996 AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. *Cell* **84** 321–330. ([https://doi.org/10.1016/S0092-8674\(00\)80986-1](https://doi.org/10.1016/S0092-8674(00)80986-1))
- Ozkan S, Murk W & Arici A** 2008 Endometriosis and infertility: epidemiology and evidence-based treatments. *Annals of the New York Academy of Sciences* **1127** 92–100. (<https://doi.org/10.1196/annals.1434.007>)
- Pan Q & Chegini N** 2008 MicroRNA signature and regulatory functions in the endometrium during normal and disease states. *Seminars in Reproductive Medicine* **26** 479–493. (<https://doi.org/10.1055/s-0028-1096128>)
- Pan Y, Ren F, Zhang W, Liu G, Yang D, Hu J, Feng K & Feng Y** 2014 Regulation of BGC-823 cell sensitivity to adriamycin via miRNA-135a-5p. *Oncology Reports* **32** 2549–2556. (<https://doi.org/10.3892/or.2014.3546>)
- Pang RT, Liu WM, Leung CO, Ye TM, Kwan PC, Lee KF & Yeung WS** 2011 miR-135A regulates preimplantation embryo development through down-regulation of E3 Ubiquitin Ligase Seven In Absentia Homolog 1A (SIAH1A) expression. *PLoS ONE* **6** e27878. (<https://doi.org/10.1371/journal.pone.0027878>)
- Planaguma J, Diaz-Fuertes M, Gil-Moreno A, Abal M, Monge M, Garcia A, Baro T, Thomson TM, Xercavins J, Alameda F et al.** 2004 A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma. *Cancer Research* **64** 8846–8853. (<https://doi.org/10.1158/0008-5472.CAN-04-2066>)
- Practice Committee of the American Society for Reproductive Medicine 2006 Endometriosis and infertility. *Fertility and Sterility* **86** S156–S160.
- Relaix F, Wei X, Li W, Pan J, Lin Y, Bowtell DD, Sassoon DA & Wu X** 2000 Pw1/Peg3 is a potential cell death mediator and cooperates with Siah1a in p53-mediated apoptosis. *PNAS* **97** 2105–2110. (<https://doi.org/10.1073/pnas.040378897>)
- Rizk B, Turki R, Lotfy H, Ranganathan S, Zahed H, Freeman AR, Shilbayeh Z, Sassy M, Shalaby M & Malik R** 2015 Surgery for endometriosis-associated infertility: do we exaggerate the magnitude of effect? *Facts, Views and Vision in ObGyn* **7** 109–118.
- Rosenwaks Z, Davis OK & Damarico MA** 1995 The role of maternal age in assisted reproduction. *Human Reproduction* **10** (Supplement 1) 165–173. ([https://doi.org/10.1093/humrep/10.suppl\\_1.165](https://doi.org/10.1093/humrep/10.suppl_1.165))
- Rubio C, Simon C, Mercader A, Garcia-Velasco J, Remohi J & Pellicer A** 2000 Clinical experience employing co-culture of human embryos with autologous human endometrial epithelial cells. *Human Reproduction* **15** (Supplement 6) 31–38. ([https://doi.org/10.1093/humrep/15.suppl\\_4.31](https://doi.org/10.1093/humrep/15.suppl_4.31))
- Ruiz-Alonso M, Blesa D & Simon C** 2012 The genomics of the human endometrium. *Biochimica et Biophysica Acta* **1822** 1931–1942. (<https://doi.org/10.1016/j.bbadis.2012.05.004>)
- Schaubach BM, Wen HY & Kellems RE** 2006 Regulation of murine Ada gene expression in the placenta by transcription factor RUNX1. *Placenta* **27** 269–277. (<https://doi.org/10.1016/j.placenta.2005.03.001>)
- Schoolcraft WB, Treff NR, Stevens JM, Ferry K, Katz-Jaffe M & Scott RT Jr** 2011 Live birth outcome with trophoctoderm biopsy, blastocyst vitrification, and single-nucleotide polymorphism microarray-based comprehensive chromosome screening in infertile patients. *Fertility and Sterility* **96** 638–640. (<https://doi.org/10.1016/j.fertnstert.2011.06.049>)

- Shapiro BS, Daneshmand ST, Desai J, Garner FC, Aguirre M & Hudson C** 2016 The risk of embryo-endometrium asynchrony increases with maternal age after ovarian stimulation and IVF. *Reproductive BioMedicine Online* **33** 50–55. (<https://doi.org/10.1016/j.rbmo.2016.04.008>)
- Sharma N, Kubaczka C, Kaiser S, Nettersheim D, Mughal SS, Riesenbergs S, Holzel M, Winterhager E & Schorle H** 2016 Tpbpa-Cre-mediated deletion of TFAP2C leads to deregulation of Cdkn1a, Akt1 and the ERK pathway, causing placental growth arrest. *Development* **143** 787–798. (<https://doi.org/10.1242/dev.128553>)
- Shebl O, Sifferlinger I, Habelsberger A, Oppelt P, Mayer RB, Petek E & Ebner T** 2017 Oocyte competence in in vitro fertilization and intracytoplasmic sperm injection patients suffering from endometriosis and its possible association with subsequent treatment outcome: a matched case-control study. *Acta Obstetrica et Gynecologica Scandinavica* **96** 736–744. (<https://doi.org/10.1111/aogs.12941>)
- Simon C, Moreno C, Remohi J & Pellicer A** 1998 Molecular interactions between embryo and uterus in the adhesion phase of human implantation. *Human Reproduction* **13** (Supplement 3) 219–232; discussion 233–216. ([https://doi.org/10.1093/humrep/13.suppl\\_3.219](https://doi.org/10.1093/humrep/13.suppl_3.219))
- Simon C, Mercader A, Garcia-Velasco J, Nikas G, Moreno C, Remohi J & Pellicer A** 1999 Coculture of human embryos with autologous human endometrial epithelial cells in patients with implantation failure. *Journal of Clinical Endocrinology and Metabolism* **84** 2638–2646. (<https://doi.org/10.1210/jcem.84.8.5873>)
- Tapia A, Vilos C, Marin JC, Croxatto HB & Devoto L** 2011 Bioinformatic detection of E47, E2F1 and SREBP1 transcription factors as potential regulators of genes associated to acquisition of endometrial receptivity. *Reproductive Biology and Endocrinology* **9** 14. (<https://doi.org/10.1186/1477-7827-9-14>)
- Tapia-Pizarro A, Figueroa P, Brito J, Marin JC, Munroe DJ & Croxatto HB** 2014 Endometrial gene expression reveals compromised progesterone signaling in women refractory to embryo implantation. *Reproductive Biology and Endocrinology* **12** 92. (<https://doi.org/10.1186/1477-7827-12-92>)
- Thoma ME, McLain AC, Louis JF, King RB, Trumble AC, Sundaram R & Buck Louis GM** 2013 Prevalence of infertility in the United States as estimated by the current duration approach and a traditional constructed approach. *Fertility and Sterility* **99** 1324.e1321–1331.e1321. (<https://doi.org/10.1016/j.fertnstert.2012.11.037>)
- Ullah K, Rahman TU, Pan HT, Guo MX, Dong XY, Liu J, Jin LY, Cheng Y, Ke ZH, Ren J et al.** 2017 Serum estradiol levels in controlled ovarian stimulation directly affect the endometrium. *Journal of Molecular Endocrinology* **59** 105–119. (<https://doi.org/10.1530/JME-17-0036>)
- Wang H** 2016 Predicting microRNA biomarkers for cancer using phylogenetic tree and microarray analysis. *International Journal of Molecular Sciences* **17** E773. (<https://doi.org/10.3390/ijms17122139>)
- Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH & Speck NA** 1996 Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. *PNAS* **93** 3444–3449. (<https://doi.org/10.1073/pnas.93.8.3444>)
- Wang B, Sheng JZ, He RH, Qian YL, Jin F & Huang HF** 2008 High expression of L-selectin ligand in secretory endometrium is associated with better endometrial receptivity and facilitates

embryo implantation in human being. *American Journal of Reproductive Immunology* **60** 127–134. (<https://doi.org/10.1111/j.1600-0897.2008.00604.x>)

**Weimar CH, Post Uiterweer ED, Teklenburg G, Heijnen CJ & Macklon NS** 2013 In-vitro model systems for the study of human embryo-endometrium interactions. *Reproductive BioMedicine Online* **27** 461–476. (<https://doi.org/10.1016/j.rbmo.2013.08.002>)

**Wenzl R, Kiesel L, Huber JC & Wieser F** 2003 Endometriosis: a genetic disease. *Drugs Today* **39** 961–972. (<https://doi.org/10.1358/dot.2003.39.12.799414>)

**Wilcox AJ, Baird DD & Weinberg CR** 1999 Time of implantation of the conceptus and loss of pregnancy. *New England Journal of Medicine* **340** 1796–1799. (<https://doi.org/10.1056/NEJM199906103402304>)

**Yang G, Zhang R, Chen X, Mu Y, Ai J, Shi C, Liu Y, Shi C, Sun L, Rainov NG et al.** 2011 MiR-106a inhibits glioma cell growth by targeting E2F1 independent of p53 status. *Journal of Molecular Medicine* **89** 1037–1050. (<https://doi.org/10.1007/s00109-011-0775-x>)

**Ying TH, Tseng CJ, Tsai SJ, Hsieh SC, Lee HZ, Hsieh YH & Bau DT** 2011 Association of p53 and CDKN1A genotypes with endometriosis. *Anticancer Research* **31** 4301–4306.

**Zhang J** 2015 Revisiting germinal vesicle transfer as a treatment for aneuploidy in infertile women with diminished ovarian reserve. *Journal of Assisted Reproduction and Genetics* **32** 313–317. (<https://doi.org/10.1007/s10815-014-0400-3>)

Received 12 September 2017

First decision 12 October 2017

Revised manuscript received 4 April 2018

Accepted 10 April 2018

**Supplementary Table I: Enriched pathways of statistically significant miRNA target genes (p<0.05) increased or decreased in the Endometriosis group compared to donor controls**

**hsa-miR-106a**

GO Term	Term	# of genes	P-Value
GO:0008284	positive regulation of cell proliferation	4	3.40E-02
GO:2000134	negative regulation of G1/S transition of mitotic cell cycle	3	6.80E-04
GO:0043066	negative regulation of apoptotic process	7	5.60E-05
GO:0051726	regulation of cell cycle	5	3.70E-05

KEGG Pathway	Pathway	# of	P-Value
--------------	---------	------	---------

		Genes	
hsa04110	Cell cycle	5	3.10E-04

### **hsa-miR-let-7b**

GO Term	Term	# of genes	P-Value
GO:2000766	negative regulation of cytoplasmic translation	3	8.30E-05
GO:0071230	cellular response to amino acid stimulus	4	1.16E-04
GO:0000082	G1/S transition of mitotic cell cycle	5	5.17E-05
GO:0051301	cell division	7	6.45E-05
GO:0001934	positive regulation of protein phosphorylation	3	0.027192
GO:0030335	positive regulation of cell migration	6	3.22E-05
GO:0008284	positive regulation of cell proliferation	5	0.014057

KEGG Pathway	Pathway	# of Genes	P-Value
hsa04914	Progesterone-mediated oocyte maturation	7	3.76E-07
hsa04152	AMPK signaling pathway	6	5.13E-05
hsa04914	Progesterone-mediated oocyte maturation	7	3.76E-07
hsa04114	Oocyte meiosis	4	0.006072
hsa04110	Cell cycle	5	7.95E-04
hsa04115	p53 signaling pathway	3	0.022282
hsa04151	PI3K-Akt signaling pathway	10	1.17E-06
hsa04068	FoxO signaling pathway	7	4.80E-06
hsa05213	Endometrial cancer	3	0.013792

### **hsa-miR-200c**

GO Term	Term	# of genes	P-Value
GO:0001525	angiogenesis	7	6.36E-04
GO:0048010	vascular endothelial growth factor receptor signaling pathway	6	2.22E-05
GO:0010595	positive regulation of endothelial cell migration	4	0.001315
GO:0001701	in utero embryonic development	7	2.49E-04
GO:0035924	cellular response to vascular endothelial growth factor stimulus	4	1.66E-04
GO:0045766	positive regulation of angiogenesis	5	0.002113

KEGG Pathway	Pathway	# of Genes	P-Value
hsa04510	Focal adhesion	9	6.30E-05

**Supplementary Table II: Enriched pathways of statistically significant miRNA target genes ( $p < 0.05$ ) increased or decreased in the AMA group**

**hsa-miR-126**

GO Term	Term	# of genes	P-Value
GO:0001938	positive regulation of endothelial cell proliferation	5	3.13E-05
GO:0045766	positive regulation of angiogenesis	5	2.29E-04
GO:0001525	angiogenesis	5	2.70E-03
GO:0048010	vascular endothelial growth factor receptor signaling pathway	3	1.53E-02

KEGG Pathway	Pathway	# of Genes	P-Value
hsa04151	PI3K-Akt signaling pathway	10	1.32E-05
hsa04012	ErbB signaling pathway	6	3.70E-05

hsa04015	Rap1 signaling pathway	7	2.86E-04
hsa04370	VEGF signaling pathway	4	2.46E-03
hsa04210	Apoptosis	4	2.59E-03
hsa04668	TNF signaling pathway	4	1.15E-02
hsa04010	MAPK signaling pathway	5	2.60E-02
hsa04664	Fc epsilon RI signaling pathway	3	3.69E-02
hsa05213	Endometrial cancer	5	7.72E-05
hsa04152	AMPK signaling pathway	5	2.01E-03

### miR-150

GO Term	Term	# of genes	P-Value
GO:0043066	negative regulation of apoptotic process	5	3.68E-03
GO:0008284	positive regulation of cell proliferation	5	4.00E-03

KEGG Pathway	Pathway	# of Genes	P-Value
hsa04110	Cell cycle	3	4.90E-02

### miR-29a

GO Term	Term	# of genes	P-Value
GO:2000352	negative regulation of endothelial cell apoptotic process	4	2.80E-04
GO:0007160	cell-matrix adhesion	5	7.75E-04
GO:0030335	positive regulation of cell migration	9	1.97E-06
GO:0048010	vascular endothelial growth factor receptor signaling pathway	3	4.32E-02

KEGG Pathway	Pathway	# of Genes	P-Value
hsa04510	Focal adhesion	16	1.81E-11
hsa04151	PI3K-Akt signaling pathway	18	3.14E-10
hsa04068	FoxO signaling pathway	7	5.17E-04
hsa04115	p53 signaling pathway	5	1.65E-03
hsa05213	Endometrial cancer	4	7.22E-03
hsa04370	VEGF signaling pathway	4	1.12E-02

### miR-29b

GO Term	Term	# of genes	P-Value
GO:0030335	positive regulation of cell migration	11	8.74E-09
GO:0051781	positive regulation of cell division	7	6.01E-08
GO:0043406	positive regulation of MAP kinase activity	7	2.42E-07
GO:0016477	cell migration	6	1.03E-03
GO:0050680	negative regulation of epithelial cell proliferation	4	2.00E-02
GO:0016049	cell growth	4	2.00E-02
GO:0043065	positive regulation of apoptotic process	7	2.22E-02
GO:0007050	cell cycle arrest	4	2.52E-02
GO:0007160	cell-matrix adhesion	8	1.48E-07
GO:0050714	positive regulation of protein secretion	6	5.25E-07
GO:2000352	negative regulation of endothelial cell apoptotic process	5	6.93E-06
GO:0048010	vascular endothelial growth factor receptor signaling pathway	3	4.11E-02

KEGG Pathway	Pathway	# of	P-Value
--------------	---------	------	---------



		<b>Genes</b>	
hsa04510	Focal adhesion	22	2.71E-19
hsa04151	PI3K-Akt signaling pathway	24	4.96E-17
hsa04014	Ras signaling pathway	9	2.51E-04
hsa04068	FoxO signaling pathway	7	4.65E-04
hsa05213	Endometrial cancer	4	6.85E-03
hsa04110	Cell cycle	6	2.27E-03
hsa04350	TGF-beta signaling pathway	5	3.53E-03
hsa04370	VEGF signaling pathway	4	1.06E-02
hsa04390	Hippo signaling pathway	5	2.64E-02
hsa05213	Endometrial cancer	4	6.85E-03
hsa04370	VEGF signaling pathway	4	1.06E-02
hsa04668	TNF signaling pathway	4	4.51E-02

**Supplementary Table III: Enriched pathways of statistically significant miRNA target genes (p<0.05) increased or decreased in Combined Differentially expressed miRNA in Association with Endometriosis Diagnosis Endometrial Cells**

<b><u>GO Term</u></b>	<b><u>Term</u></b>	<b><u># of genes</u></b>	<b><u>P-Value</u></b>
<a href="#"><u>GO:0000082</u></a>	<a href="#"><u>G1/S transition of mitotic cell cycle</u></a>	<a href="#"><u>12</u></a>	<a href="#"><u>4.01E-12</u></a>
<a href="#"><u>GO:0051301</u></a>	<a href="#"><u>cell division</u></a>	<a href="#"><u>8</u></a>	<a href="#"><u>0.002112036</u></a>
<a href="#"><u>GO:0001701</u></a>	<a href="#"><u>in utero embryonic development</u></a>	<a href="#"><u>7</u></a>	<a href="#"><u>3.96E-04</u></a>
<a href="#"><u>GO:0060070</u></a>	<a href="#"><u>canonical Wnt signaling pathway</u></a>	<a href="#"><u>4</u></a>	<a href="#"><u>0.00887545</u></a>
<a href="#"><u>GO:0016055</u></a>	<a href="#"><u>Wnt signaling pathway</u></a>	<a href="#"><u>4</u></a>	<a href="#"><u>0.071185563</u></a>
<a href="#"><u>GO:0048599</u></a>	<a href="#"><u>oocyte development</u></a>	<a href="#"><u>3</u></a>	<a href="#"><u>0.001949408</u></a>
<a href="#"><u>GO:2001234</u></a>	<a href="#"><u>negative regulation of apoptotic signaling pathway</u></a>	<a href="#"><u>3</u></a>	<a href="#"><u>0.002969315</u></a>

<a href="#">GO:0045766</a>	<a href="#">positive regulation of angiogenesis</a>	<a href="#">6</a>	<a href="#">3.09E-04</a>
<a href="#">GO:0001525</a>	<a href="#">angiogenesis</a>	<a href="#">6</a>	<a href="#">0.005756441</a>

<b><u>KEGG Pathway</u></b>	<b><u>Pathway</u></b>	<b><u># of Genes</u></b>	<b><u>P-Value</u></b>
<a href="#">hsa04151</a>	<a href="#">PI3K-Akt signaling pathway</a>	<a href="#">16</a>	<a href="#">3.01E-07</a>
<a href="#">hsa04110</a>	<a href="#">Cell cycle</a>	<a href="#">13</a>	<a href="#">8.02E-10</a>
<a href="#">hsa04115</a>	<a href="#">p53 signaling pathway</a>	<a href="#">7</a>	<a href="#">2.92E-05</a>
<a href="#">hsa04390</a>	<a href="#">Hippo signaling pathway</a>	<a href="#">8</a>	<a href="#">4.11E-04</a>
<a href="#">hsa05213</a>	<a href="#">Endometrial cancer</a>	<a href="#">5</a>	<a href="#">0.001224143</a>
<a href="#">hsa04310</a>	<a href="#">Wnt signaling pathway</a>	<a href="#">6</a>	<a href="#">0.008213403</a>
<a href="#">hsa04510</a>	<a href="#">Focal adhesion</a>	<a href="#">9</a>	<a href="#">5.15E-04</a>
<a href="#">hsa04370</a>	<a href="#">VEGF signaling pathway</a>	<a href="#">4</a>	<a href="#">0.017862483</a>
<a href="#">hsa04350</a>	<a href="#">TGF-beta signaling pathway</a>	<a href="#">5</a>	<a href="#">0.007023653</a>
<a href="#">hsa04068</a>	<a href="#">FoxO signaling pathway</a>	<a href="#">5</a>	<a href="#">0.033410186</a>
<a href="#">hsa04010</a>	<a href="#">MAPK signaling pathway</a>	<a href="#">6</a>	<a href="#">0.081996404</a>